Does Cutting Out a Keloid Make It Grow Back Worse? A Myth Check

Ask anyone who has lived with a keloid for a few years and you will likely hear the same warning: never let a surgeon cut it out, because it will come back bigger. This belief is widespread, and it is not entirely wrong. But it is also not entirely right, and the difference matters for people weighing real treatment decisions.

The claim: surgical excision of a keloid guarantees a larger, angrier recurrence.

The verdict: partially true for excision alone, largely outdated for excision combined with adjuvant therapy.

First, the biology. A keloid is not simply a thick scar. It is the result of a wound-healing process that fails to shut off. In normal healing, fibroblasts produce collagen for a period of weeks, then receive signals to slow down, and the scar remodels and flattens over months. In keloid-prone skin, fibroblasts remain overactive. They respond abnormally to growth factors, particularly transforming growth factor beta, and they keep depositing dense collagen well past the point of wound closure. The lesion grows beyond the borders of the original injury, which is the defining feature that separates keloids from hypertrophic scars.

Now consider what excision does. Removing a keloid with a scalpel creates a fresh surgical wound in the exact tissue that has already demonstrated it cannot regulate healing. The same dysregulated fibroblast population, the same inflammatory signaling environment, the same genetic predisposition are all still present. Cutting does not remove the tendency, only the visible product of it. This is why published recurrence rates for excision alone typically fall somewhere between 45 and 100 percent depending on the study, the body site, and how long patients were followed. Earlobes tend to do better. The chest, shoulders, and upper back, areas under constant skin tension, tend to do worse. So the folk wisdom has a real foundation: excision by itself is a gamble with poor odds, and a recurrent keloid can indeed exceed the original in size because the surgical wound is often larger than the initial injury that triggered the first keloid.

Here is where the myth breaks down. Modern keloid management almost never relies on excision alone. The standard approach pairs surgery with an adjuvant, meaning a second treatment designed to suppress the abnormal healing response during the critical weeks after the wound closes. The most studied combinations include the following.

Excision plus corticosteroid injection. Triamcinolone injected into the wound edges at the time of surgery and at intervals afterward suppresses inflammation and reduces fibroblast collagen production. Reported recurrence rates with this combination generally drop below 50 percent, often considerably lower with disciplined follow-up.

Excision plus radiation. Superficial radiotherapy or brachytherapy delivered within 24 to 72 hours of surgery targets the rapidly dividing fibroblasts before they can rebuild the lesion. Multiple case series report recurrence rates in the range of roughly 10 to 20 percent, making this one of the most effective combinations for stubborn or large keloids. The tradeoff is a small theoretical long-term risk from radiation exposure, which is why clinicians reserve it for cases where the burden of the keloid justifies it and shield surrounding tissue carefully.

Excision plus pressure therapy. For earlobe keloids, custom pressure earrings worn for months after surgery mechanically limit blood flow and collagen deposition. This low-tech adjuvant performs surprisingly well at that specific site.

Excision plus 5-fluorouracil or other antimetabolites. These agents interfere with fibroblast proliferation directly and are sometimes combined with steroids to reduce steroid side effects such as skin thinning.

The common thread is timing. The window immediately after surgery, roughly the first several weeks, is when the recurrence is either prevented or seeded. Patients who undergo excision and then skip the adjuvant appointments effectively convert a combination protocol back into excision alone, and the statistics follow accordingly. Clinicians who treat keloids regularly describe adherence to the follow-up schedule as the single most controllable variable in the outcome.

A few honest caveats. No combination brings recurrence to zero. Keloid biology varies between individuals, and people with darkly pigmented skin, a strong family history, or lesions on high-tension sites face steeper odds regardless of technique. Recurrences, when they happen, usually appear within the first year but can emerge later, so a keloid that looks quiet at six months has not fully declared itself. And surgery is not always the right first step. Smaller, younger keloids often respond to injections, laser, or cryotherapy alone, and avoiding a new wound entirely is sometimes the smarter play.

So the myth deserves an update rather than a debunking. Cutting out a keloid and doing nothing else is genuinely risky, and the fear behind the folk wisdom earned its place. But excision inside a planned protocol, with an adjuvant chosen for the site and the patient, is a legitimate and often successful option. The question to ask is not whether surgery is on the table. It is what happens in the six weeks after the stitches come out.

Related reading: Why Cutting a Keloid Out Rarely Ends the Story: The Case for Combination Therapy After Excision.

Further reading: Analysis of Therapeutic Interventions for Hypertrophic and Keloid Scarring: A Systematic Review (J Drugs Dermatol 2025); Keloid management: a review of treatment modalities (Ital J Dermatol Venerol 2025); Pathogenesis, attenuation, and treatment strategies for keloid management (Tissue Cell 2025).